4-氟代苯基甲苯 | 28593-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟代苯基甲苯
• 中文别名: 1-氟-4-戊基苯；4-氟戊基苯
• 英文名称: 1-fluoro-4-pentylbenzene
• CAS: 28593-14-8
• 化学式: C₁₁H₁₅F
• mdl: MFCD00079760
• 分子量: 166.239
• InChiKey: UUAAALCIWZDBDT-UHFFFAOYSA-N

物化性质

• 沸点：
  105 °C
• 密度：
  0,94 g/cm3
• 闪点：
  73℃
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，也未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2903999090
• 安全说明：
  S26,S36

反应信息

• 作为反应物：
  描述：

  4-氟代苯基甲苯 在 Oxone 、 manganese(III)-5,10,15,20-tetrakis(pentafluorophenyl)porphyrin chloride 、 碘苯二乙酸 、 水 作用下， 以 乙腈 为溶剂， 以49 %的产率得到1-[4-(氟)-苯基]戊烷-1,4-二酮
  参考文献：
  名称：

  Manganese(iii) porphyrin-catalyzed regioselective dual functionalization of C(sp³)–H bonds: the transformation of arylalkanes to 1,4-diketones

  摘要：

  我们已经开发出一种完整的方法，可以在温和条件下，高选择性地使用水作为主溶剂和最基本的锰（III）卟啉配合物作为催化剂，将芳基烷烃氧化为1,4-二酮。

  DOI：

  10.1039/d2cc06126k
• 作为产物：
  描述：

  acetic 5-(4-fluorophenyl)pentanoic peroxyanhydride 以 various solvent(s) 为溶剂， 生成 氯甲烷 、 4-氟代苯基甲苯 、 1-(4-氯丁基)-4-氟苯
  参考文献：
  名称：

  Structure of .omega.-arylalkyl radicals: a carbon-13 CIDNP investigation

  摘要：

  DOI：

  10.1021/jo00155a006
• 作为试剂：
  描述：

  2-(3,5-二甲氧基苯基)-5-(4-氟苯基)-戊烷 、 溶剂黄146 、 氢溴酸 、 氢气 在 乙醚 、 甲烷 、 magnesium sulfate 、 2-(3,5-dihydroxyphenyl) 、 4-氟代苯基甲苯 作用下， 以 水 为溶剂， 87.0~180.0 ℃ 、177.32 Pa 条件下， 反应 18.0h， 以to yield 45 g的产率得到2-(3,5-dihydroxyphenyl)-5-(4-fluorophenyl)pentane
  参考文献：
  名称：

  × Mangave plant named ‘Man of Steel’

  摘要：

  一种新的独特×Mangave植物，名为“钢铁之人”，其特点是具有众多、细长、纤维状、扁平、带有灰紫色边缘和微小齿齿的重度灰绿色叶子，呈现略微直立的习性。年轻的叶子在暴露于紫外线下时显示出淡淡的葡萄酒斑点。

  公开号：

  USPP029196P2

文献信息

• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS
  申请人：Herdewijn Piet

  公开号：US20120046278A1

  公开（公告）日：2012-02-23

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

  本发明涉及式I、II、III或IV的化合物，及/或其药用可接受的加合盐和/或其立体异构体和/或其溶剂化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求1所定义。本发明还涉及它们的制备方法，以及其药物组合物。本发明进一步涉及所述化合物作为生物活性成分的用途，更具体地作为治疗疾病和病理状况的药物，例如但不限于免疫和自身免疫性疾病、器官和细胞移植排斥反应。
• Antiviral Activity of Novel Bicyclic Heterocycles
  申请人：De Jonghe Steven

  公开号：US20130190297A1

  公开（公告）日：2013-07-25

  The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加盐物和/或其立体异构体和/或其溶剂合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，并且涉及使用这些化合物来治疗或预防病毒感染以及用于制造用于治疗或预防病毒感染的药物，特别是属于逆转录病毒科、黄病毒科和小核病毒科家族的RNA病毒感染，更具体地是与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒等肠病毒感染相关的感染。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防病毒感染。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗病毒性疾病和病理状况的药物，例如但不限于与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒相关的病毒感染。
• BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Katayama Seiji

  公开号：US20130116227A1

  公开（公告）日：2013-05-09

  Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)

  揭示了一种表示为公式（1）的新型联苯酰胺衍生物，具有与醛固酮受体的亲和力；还揭示了其药用可接受的盐。（在该公式中，A是由公式（a）表示的任何基团之一；L是—CONH—等；R1是可替代的氨基磺酰基等；R2是氢原子等；R3是氢原子等；R4是氢原子、卤原子、羟基、可替代的氨基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环氨基基团等；R5a、R5b和R5c各自独立地是氢原子等；R6是卤原子、氰基等；R7和R8各自独立地是氢原子等；m是整数，例如0。）
• Computational and Experimental Studies of Phthaloyl Peroxide-Mediated Hydroxylation of Arenes Yield a More Reactive Derivative, 4,5-Dichlorophthaloyl Peroxide
  作者：Andrew M. Camelio、Yong Liang、Anders M. Eliasen、Trevor C. Johnson、Changxia Yuan、Alex W. Schuppe、K. N. Houk、Dionicio Siegel

  DOI：10.1021/acs.joc.5b01079

  日期：2015.8.21

  experimentally determined to possess enhanced reactivity, has expanded the scope of the reaction while maintaining a high level of tolerance for diverse functional groups. The reaction proceeds through a novel “reverse-rebound” mechanism with diradical intermediates. Mechanistic insight was achieved through isolation and characterization of minor byproducts, determination of linear free energy correlations, and

  用邻苯二甲酰过氧化试剂氧化芳烃提供了一种合成苯酚的新方法。通过计算预测并实验确定具有增强的反应性的新的，更具反应性的芳烃氧化剂4,5-二氯邻苯二甲酰过氧化物扩大了反应范围，同时保持了对各种官能团的高度耐受性。该反应通过具有双自由基中间体的新型“逆向反弹”机理进行。通过分离和表征次要副产物，确定线性自由能的相关性以及对芳烃的取代基效应进行计算分析，从而获得了机理上的见解，每一项都为通过双自由基途径进行的反应提供了额外的支持。